Vulvovaginal Graft-Versus-Host Disease.

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Vulvovaginal chronic graft-versus-host disease (cGVHD) is an underrecognized complication after allogeneic hematopoietic stem cell transplantation (HCT).
• Genital involvement in cGVHD often co-occurs with manifestations in the mouth, eyes, and skin.
• Female HCT recipients face increased risks for condylomas, cervical dysplasia, and neoplasia.

Purpose of the Study:

• To highlight the importance of early recognition and diagnosis of vulvovaginal cGVHD.
• To discuss the clinical and histological features that aid in diagnosing vulvovaginal cGVHD.
• To outline current treatment strategies for vulvovaginal cGVHD.

Main Methods:

• Review of clinical presentations and histological findings of vulvovaginal cGVHD.
• Correlation of genital cGVHD with other organ involvement.
• Examination of treatment modalities including topical immunosuppression, dilator use, and estrogen therapy.

Main Results:

• Vulvovaginal cGVHD can mimic other inflammatory vulvar conditions, necessitating a high index of suspicion in the appropriate clinical context.
• Early identification of genital involvement is key to preventing severe sequelae.
• Standardized guidelines for HCT patient care by organ system are available through the National Institutes of Health.

Conclusions:

• Vulvovaginal cGVHD is a significant, though often overlooked, post-transplant complication.
• Prompt diagnosis and management, guided by clinical context and histology, are essential for optimal patient outcomes.
• Awareness and adherence to established guidelines are critical for managing HCT recipients at risk.